We are live on ! Find out more
LXRX icon

Lexicon Pharmaceuticals
LXRX

115 hedge funds and large institutions have $445M invested in Lexicon Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 31 increasing their positions, 32 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 13

88% more call options, than puts

Call options by funds: $1.74M | Put options by funds: $928K

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

44% more capital invested

Capital invested by funds: $308M → $445M (+$136M)

12% more funds holding

Funds holding: 103 → 115 (+12)

4.47% more ownership

Funds ownership: 96.38% → 100.86% (+4.5%)

3% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 32

Holders
115
Holders Change
+12
Holders Change %
+11.65%
% of All Funds
2.27%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.06%
New
26
Increased
31
Reduced
32
Closed
13
Calls
$1.74M
Puts
$928K
Net Calls
+$816K
Net Calls Change
+$951K

Top Buyers

1
Two Sigma Investments
Two Sigma Investments
New York
+$3.33M
2
Marshall Wace
Marshall Wace
United Kingdom
+$3.28M
3
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$2.67M
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$2.35M
5
AQR Capital Management
AQR Capital Management
Connecticut
+$2.1M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.02M
2
Macquarie Group
Macquarie Group
Australia
-$1.69M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.59M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$828K
5
TAM
TFG Asset Management
Cayman Islands
-$611K
Name Holding Trade Value Shares
Change 		Change in
Stake
SIM
26
Spark Investment Management
New York
$1.51M +$1.4M +363,100 New
Citadel Advisors
27
Citadel Advisors
Florida
$1.32M +$438K +113,844 +56%
Two Sigma Advisers
28
Two Sigma Advisers
New York
$1.2M +$870K +226,100 +355%
Charles Schwab
29
Charles Schwab
California
$1.09M +$121K +31,439 +14%
T. Rowe Price Associates
30
T. Rowe Price Associates
Maryland
$803K +$506K +131,545 +213%
Barrow, Hanley, Mewhinney & Strauss
31
Barrow, Hanley, Mewhinney & Strauss
Texas
$748K +$694K +180,194 New
GCP
32
GSA Capital Partners
United Kingdom
$745K +$691K +179,481 New
Acadian Asset Management
33
Acadian Asset Management
Massachusetts
$685K +$635K +164,948 New
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$676K +$566K +147,109 +927%
N
35
Nuveen
North Carolina
$658K -$58.1K -15,081 -9%
Goldman Sachs
36
Goldman Sachs
New York
$599K -$153K -39,720 -22%
Axa
37
Axa
France
$559K +$195K +50,702 +60%
VEA
38
Virtus ETF Advisers
New York
$545K +$33.2K +8,632 +7%
SO
39
STRS Ohio
Ohio
$534K +$496K +128,900 New
Federated Hermes
40
Federated Hermes
Pennsylvania
$466K +$432K +112,326 +158,206%
LI
41
Leap Investments
Illinois
$450K +$417K +108,399 New
Squarepoint
42
Squarepoint
New York
$439K +$408K +105,889 New
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$431K +$17.1K +4,449 +4%
Deutsche Bank
44
Deutsche Bank
Germany
$420K -$98.9K -25,697 -20%
AllianceBernstein
45
AllianceBernstein
Tennessee
$409K – – –
Swiss National Bank
46
Swiss National Bank
Switzerland
$368K – – –
ACI
47
AMP Capital Investors
Australia
$366K +$340K +88,400 New
BC
48
Birchview Capital
Vermont
$332K – – –
Stifel Financial
49
Stifel Financial
Missouri
$298K -$7.33K -1,904 -3%
Wells Fargo
50
Wells Fargo
California
$298K +$192K +49,959 +227%
1
2
3 4 5

LXRX Hedge Fund Activity: Q4 2019 in Review

115 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2019, worth a combined $445M — up 44% from $308M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new LXRX positions and 13 closed out — a net gain of 13 holders — while 31 added to existing stakes and 32 trimmed.

The largest buyer was Two Sigma Investments, adding an estimated $3.33M. The largest seller was Fidelity Investments, cutting an estimated $2.02M.

  • 115 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2019, up from 103 in Q3 2019.
  • Funds reported $445M of Lexicon Pharmaceuticals stock for Q4 2019, up 44% quarter-over-quarter.
  • 26 funds opened new Lexicon Pharmaceuticals positions in Q4 2019 and 13 closed out, a net change of +13 holders.
  • The largest Lexicon Pharmaceuticals buyer in Q4 2019 was Two Sigma Investments, an estimated $3.33M added.
  • The largest Lexicon Pharmaceuticals seller in Q4 2019 was Fidelity Investments, an estimated $2.02M sold.

Based on aggregated 13F filings for Q4 2019.